10 research outputs found
The longitudinal changes in the prevalence of NAFLD stratified by the <i>PNPLA3</i> genotype among normal weight subjects.
<p>The prevalence of NAFLD is shown as solid, dashed-dotted and dotted lines in the subjects with the <i>PNPLA3</i> C/C, C/G and G/G genotypes, respectively. NAFLD, non-alcoholic fatty liver disease; PNPLA3, patatin-like phospholipase 3.</p
Clinical characteristics of the subjects for the analyses regarding the risk of NAFLD.
<p>The data are the means ± standard deviation, median (range) for skewed variables, or the numbers of subjects (%) for categorical variables.</p><p><sup>a</sup> Fisher’s exact test.</p><p><sup>b</sup> Mann–Whitney U test (otherwise, Student’s t-test was used).</p><p>NAFLD, non-alcoholic fatty liver disease; BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyl transferase; PNPLA3, patatin-like phospholipase 3.</p><p>Clinical characteristics of the subjects for the analyses regarding the risk of NAFLD.</p
Specific examples of the optimal trough concentration of VPA for simulated patients.
<p>VPA, valproic acid; AED, antiepileptic drug; PHT, phenytoin; SCN1A, sodium channel neuronal type I alpha subunit.</p><p>Specific examples of the optimal trough concentration of VPA for simulated patients.</p
The results of the visual predictive check of the population PK-PD model.
<p>The solid line represents the observed proportion with a more than 50% reduction in seizure frequency, and the solid area represents the 95% prediction interval. PK, pharmacokinetic; PD, pharmacodynamics; VPA, valproic acid.</p
Comparison of Risk Prediction Models before and after adding <i>H</i>. <i>pylori</i> and IL-1 polymorphisms.
<p>Comparison of Risk Prediction Models before and after adding <i>H</i>. <i>pylori</i> and IL-1 polymorphisms.</p
Prevalence of STEMI according to the current smoke exposure and the coincidence of <i>Helicobacter pylori</i> seropositivity and interleukin-1 polymorphisms.
<p>STEMI, ST-segment elevation myocardial infarction.</p
Clinical characteristics according to simultaneous presence of <i>H</i>. <i>pylori</i> and IL-1 polymorphisms.
<p>Clinical characteristics according to simultaneous presence of <i>H</i>. <i>pylori</i> and IL-1 polymorphisms.</p
Prevalence of the coincidence of <i>Helicobacter pylori</i> seropositivity and interleukin-1 polymorphisms between NSTE-ACS and STEMI groups.
<p>NSTE-ACS, non-ST-segment elevation acute coronary syndrome; STEMI, ST-segment elevation myocardial infarction.</p